Tag Archives: business
The Health Care Sector’s Weakness Could Be The Investor’s Best Friend
Summary The health care sector went through a significant meltdown during the recent weeks. A long term investor might consider it as an opportunity to invest in great companies. Here is a list of 4 non-expensive ETFs that are focused on the Health Care sector. Three weeks ago a good friend of mine bought shares of Mylan Inc (NASDAQ: MYL ). His goal was to invest in a defensive stock in order to mitigate the volatile market. Since the day he made the purchase the stock was hammered down and closed is currently at a total of ~20% lower. Mylan is a global generic and specialty pharmaceuticals company that is registered in the Netherlands. In 2007, following a big acquisition Mylan became the second-largest generic and pharmaceuticals’ company in the United States. It was a wise decision at the time. Here is Mylan’s forecast P/E growth rates in the coming years based on Nasdaq.com. A P/E of 8x for a double digit growth company is not too bad at all. MYL’s stock price free fall was no different compared to other Health care companies’ stocks. If looking at the behavior of the S&P 500 Health Care Sector the graph tells us that there was about 20% drop in the sector since the recent highs. On Wednesday, September 30th, there seemed to be some recovery after several bloody weeks. (click to enlarge) The drop is explained by Hillary Clinton’s ” price gouging ” tweet which led to concerns within the investors’ community regarding higher regulations on drug pricing. Is this massive drop justified or is it an out-of-panic oversell and therefore a great opportunity? Why do I think it is an oversell? Several reasons lead me to believe it is an extreme reaction over nothing and it is a temporary meltdown: The market is very volatile in the recent weeks and it seems that the focus is only on the bad news that are being a catalyst towards a dipper correction. Back in August it was the less-than-expected growth in China’s economy, than it was the Volkswagen ( OTCQX:VLKAY ) scandal and now it is this tweet. Any regulation would need to pass Congress where the Republicans still have the major votes. It would be at least couple of years until something would really change. Not all companies are taking outrages profits on their developed drugs. The amount of Research and Development the companies are investing is huge and therefore the economy of the business will eventually dictate the prices. It will not be the politicians. The sector is composed from different types of companies. Some develop an original medicine or drug and there are generic drug companies. Some are focused on specific niches and others have huge diversification. Even if there will be new regulations not all will suffer equally. Some would even benefit from it. For those, like me, who think that it is the later here are some ETFs that invest in this sector and should be profoundly examined by the long term investor. Why an ETF and not specific stock picking? While both the uncertainty and the volatility are high an investment in a specific sector can be better managed through an ETF. In cases where an investor would like to build a position that is composed by wide list of holdings, sometimes in several steps, an ETF would be a better way to do it. Buying into a sector’s ETF allows to build a position in a by-step model. Another reason to prefer an ETF is the level of familiarity with the list of companies in the sector. Though all the sector’s companies were hurt by the recent selloff most of the investors will not know which of the companies are best to recover and which could be impacted by new regulations (in case it is not just a hot balloon towards election). An ETF allows to have a wide exposure and by that increase the probability to ride the right companies towards recovery. When looking at the list of Health care ETFs I found a list of 38 ETFs. The full list can be found here . Some of the ETFs are focused on the traditional big health care companies like Johnson & Johnson (NYSE: JNJ ), Gilead (NASDAQ: GILD ) and Pfizer (NYSE: PFE ). Others are focused on biotechnology companies like BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) and Biogen Inc. (NASDAQ: BIIB ). Some are focused on health care equipment companies and some in small biotech small startups. An investor can decide based on his or her risk profile the best ETF that suits his or her needs based on its mix and focus. Filtering the list As I like to start a list filtering by eliminating ETF that charge high management fees I have sorted out all ETFs that charge more that 0.3% per year. Surprisingly I was left with only four ETFs. (click to enlarge) The last four are: The Health Care Select Sect SPDR ETF (NYSEARCA: XLV ), which replicates Health Care Select Sector Index. The Vanguard Health Care ETF (NYSEARCA: VHT ), which replicates MSCI US Investable Market Health Care 25/50 Index. The Fidelity MSCI Health Care Index ETF (NYSEARCA: FHLC ) that replicates MSCI USA IMI Health Care Index. The PowerShares S&P SmallCap Health Care Portfolio ETF (NASDAQ: PSCH ) which replicate S&P SmallCap 600 Health Care Index. This list allows an investor to pick an inexpensive ETF based on his or her own risk tolerance. A quick comparison between the four: In term of performance, PSCH delivered the highest return in the last five years due to its more risky nature. Surprisingly it wasn’t harmed harder than the others during the recent month drop. Both XLV and VHT are tending towards the large cap health care companies. XLV seems to be more conservative as it shown by its average 18x P/E ratio versus the average of 32x. VHT has a significantly higher amount of holdings which are mostly small and medium cap companies that are trading at higher P/Es compared to the JNJs and PFEs. Conclusions: The list of four non-expensive ETFs can be examined by a long term investor who believes that the Health Care sector’s meltdown is only a temporary one. In term of the potential of long term gains, some would prefer the small cap ETF, PSCH. If looking for high diversification, VHT seems to be the best one. I picked XLV in term of risk/return tradeoff. I prefer an exposure to the big and strong companies of the sector. In any case, I suggest to plan a strategy of building a position in multiple steps. The volatility is still here and the correction can be dipper than anyone anticipates. Happy investing.
How Not To Wipe Out With Momentum
Summary Implementation costs and front-running make an index replication strategy inadvisable as a means to capture the momentum premium. The proven profitability and robustness of momentum must be balanced against the vulnerability to crashes and crowded trades. Combining value and momentum in order to exploit their typically negative correlation in stock holdings and alpha can improve a portfolio’s Sharpe ratio over that of either strategy alone. Momentum investors are like the surfers we watch from beaches along the Pacific coast. Both must catch a wave. Both attempt to ride it as it breaks. But the ability to glide away smoothly before being caught inside the inevitable crash(ing wave) that follows is what determines success. Momentum, one of a handful of equity factors that empirically displays robust equity returns, has recently become popular as investors explore factor investing. In the passive realm, investors are increasingly seeking to replicate cheap and transparent indices. But does index replication make sense in the case of momentum? We believe a momentum strategy implemented through an index-based approach has serious limitations. And although some active managers are quite adept at riding the momentum wave, it does require significant experience and skill. Our view is that momentum as an index replication strategy can be very dangerous, but incorporating it into an active value strategy is an opportune way to exploit its insights. Catching the Wave The investment industry borrowed the term “momentum” from the physical sciences. In physics, momentum is defined as mass (such as ocean water) in motion. When used in the sense of investing, momentum refers to movement in stock prices. Several explanations exist for the energy that creates the prolonged movement of stock prices higher or lower. The most convincing explanation, in our view, is that investors initially underreact to earnings surprises. Chordia and Shivakumar (2006) and Novy-Marx (2015) have shown that earnings momentum explains most of the momentum effect. Investors are, at first, slow to react to an unexpected uptick or downtick in earnings. But when the next earnings data are reported and they confirm the prior report, investors register the potential importance of the change in trend. If earnings are higher than expected, the momentum in price is upward. Subsequent confirming earnings releases may even cause euphoria and over-extrapolation of future earnings forecasts, reinforcing the fast-moving upward trajectory. The momentum investor benefits as the price reacts to subsequent earnings announcements and moves higher. Price momentum can also move in the opposite direction – down – with correspondingly negative outcomes for investors. We will discuss this “fly in the sunscreen” in the next section. Investors have good reason to want to catch the momentum wave. History shows that stocks with above-average performance in the prior year have tended to persist in producing short-term excess returns. This tendency is one of the strongest empirical regularities in finance, and has been documented across geographies and asset classes. Table 1 reports the average performance of momentum equity portfolios constructed for different definitions of momentum 1 and in different geographical markets: the United States, Europe, Japan, Asia-Pacific ex Japan, and Global. Momentum has consistently added value across markets, with the widely known exception of Japan – an outlier we would expect for any strategy with inherent randomness. (click to enlarge) The data also show that the risk-return characteristics of momentum are robust across time periods. Figure 1 plots the growth of one U.S. dollar invested in a momentum strategy in January 1927. By the end of the 87-year period in June 2015, it had grown quite steadily to a formidable $6,524, which compares to $4,078 for the market portfolio. (click to enlarge) Wiping Out Buying into positive price momentum – that is, purchasing a stock whose price subsequently and steadily rises – generates a capital gain for an investor. The catch is that, as in physics, what goes up must come down. The perfectly breaking 15-foot wave can quickly become dangerous and deadly. Predicting when that turning point will be, just as forecasting when the turning point in the price momentum of a particular stock or asset class will arrive, is no easy task. Missing that turning point can mean not only not locking in a gain, but more insidiously, being “caught inside the wave”, unable to sell before the downside of a momentum trend takes hold in the market. Accordingly, two predominant risks characterize a momentum strategy: substantial drawdowns, or crashes, and a crowded momentum trade, which makes the trading costs high enough to obliterate the alpha of the strategy for the careless momentum surfer. Let’s take a closer look at both of these. The crashes periodically experienced in a momentum strategy can be significant, as Figure 2 shows. The relentless upward climb of prices depicted in Figure 1 disguises (thanks to the log-scale of the chart) the sudden and abrupt drawdowns that a momentum investor must live with. These drawdowns usually occur following periods of heightened volatility, typically a function of a crisis event. Since 1927, drawdowns have generally been under 20%, but the granddaddy of all drawdowns was the 74% plunge in prices in the aftermath of the Great Depression. In the last 15 years, the U.S. equity market has been visited with two major negative momentum events: the first, a 31% drawdown after the tech bubble burst in 2000, and the second, a 57% drawdown in the wake of the 2008 global financial crisis. (click to enlarge) In a crash, the price momentum is typically concentrated in groups of stocks that the market particularly loathes and fears more than others, often distressed companies with high betas. These recent losers are sold as the negative momentum continues, until investors, satisfied with the new state of the world, view these stocks as cheap enough to be great investment opportunities. As the market shifts its perspective, the most-feared losers with high betas recover with a vengeance, and momentum investors are off to catch another wave. Crowded surf can create frustration as surfers compete for waves, leading to low wave counts and disappointing rides. The same experience looms for investors who chase the momentum trade. Momentum investors face the probability of a lower return as they “crowd in” to purchase a stock benefitting from positive momentum, which pushes the price up beyond fair value. When the momentum trend begins to reverse, momentum investors face the risk of not being able to sell at a reasonable price as large numbers “crowd out” to liquidate their positions. Essentially, the higher the price goes, the more investors are attracted to the trade, lowering its potential return except to the earliest adopters. Likewise, the lower the price goes, the faster investors seek to exit the trade, putting significant pressure on the price and the market’s ability to absorb the extent of the selling interest. The substantial risk from these interrelated forces – drawdowns and the crowded trade – act as a very practical and meaningful deterrent to more widespread adoption of a momentum investing strategy, even though it has been proven to be robustly profitable. Being cognizant of these risks, how can an investor best exploit the insights of a momentum strategy? Navigating Dangerous Currents A surfer knows to look for rip currents that can push her away from shore. In investing, particularly in passive strategies, dangerous currents lurk in the implementation process. One of these currents, the far-from-trivial price impact of rebalancing in popular indices, has been studied by a number of researchers: Shilfer (1986), Harris and Gurel (1986), Arnott and Vincent (1986), Goetzmann and Garry (1986), Jain (1987), Lamoureux and Wansley (1987), and Lynch and Mendenhall (1997), among others. Other researchers, including Novy-Marx and Velikov (2014) and Hsu et al. (forthcoming), have estimated the trading costs associated with index-like implementation of a momentum strategy. Hsu and his co-authors calculate the value added by a momentum strategy before and after transaction costs, as reported in Table 2 . The calculation shows that trading costs are higher than the potential benefits from the strategy. (A caveat: We do not believe this to be true in the case of an active manager with strong expertise in trading. 2 ) (click to enlarge) The practical implication of tracking an index, regardless of factor, is that when one investor places her rebalancing trades, all the other investors tracking the same index are also placing their rebalancing trades. Consequently, these investors are competing for the same stocks at the same time, generating upward pressure on price. When the factor is momentum, this phenomenon is aggravated by the fact that in order to squeeze the highest performance out of a momentum strategy, turnover of close to 100% a month is required. Thus, in the hands of inefficient implementers or automated indices, high turnover can mean high cost. Other currents that plague the implementation of passive strategies are the required transparency and broad disclosure of index rules. With today’s state-of-the-art technology, modern-day front-runners are able to reproduce index calculations and implement trades well before rebalancing announcements are made by the index calculator. Therefore, spreading trades over time cannot remedy the problem of prices pushed up significantly by front-running activity. As such, the front-runners will enjoy the factor premium – in this case, the momentum premium – and the index investors will provide this premium to them. Riding the Curl A pure momentum strategy, as we have just outlined, has both pros (demonstrated profitability and robustness) and cons (crashes and crowded trades). One strong “pro” we have yet to mention is the contribution that momentum can make to a value strategy. Adding momentum to a value strategy is similar to a surfer riding “peaky” waves that will give him a lengthy and exciting ride, leaving others to surf “close-out” waves with short, dull rides. In a value strategy, investors sometimes find themselves trading against momentum. As a stock becomes cheaper, a value strategy suggests buying more of it – the exact opposite of what a momentum strategy suggests. Not surprisingly, value and momentum strategies are usually negatively correlated, both in terms of stock holdings and alpha. Exploiting this negative correlation is essentially riding the curl – a value strategy conditioned on momentum. The combined strategy generally trades like a value strategy, but with purchases and sales delayed to benefit from momentum’s impact on prices. The addition of momentum need not boost turnover relative to a value investing strategy, and therefore, need not incur the high trading costs of a momentum strategy. Table 3 illustrates that combining value and momentum in a single strategy leads to significant improvements in portfolio risk-return characteristics. The improvements, largely attributable to consistent negative correlation that varies between -0.2 and -0.4, are robust. As shown in Table 3, the 50% value/50% momentum strategy’s Sharpe ratios are markedly higher than those for either strategy alone, indicating that a value strategy conditioned on momentum produces a significantly improved risk-return trade-off across regions, with the exception of Japan. (click to enlarge) Pipelining Momentum On paper, a momentum-based index against which active managers can benchmark makes sense – momentum is an important market driver that cannot be ignored. But in our opinion, passive implementation of a momentum strategy is not advisable. Front-runners and high transaction costs, a function of the strategy’s required high turnover, largely destroy the potential benefits of a momentum-based passive portfolio. Certainly, an active implementation of a momentum strategy, which incorporates a careful study of liquidity, makes sense for some investors. The more sophisticated investors who are aware of the strategy’s risks of crashes and crowded trades can benefit, but only when carefully implemented. Thus, the implementation capabilities of an active manager of a momentum strategy should be reviewed just as rigorously as, if not more so, the manager’s trading expertise. In our view, both passive and active standalone momentum-based strategies have the potential to wipe out the value-add that the momentum premium can bring to a portfolio. But incorporating momentum into a value strategy can open a performance pipeline for the investor who can make a clean escape as the wave closes behind him, crashing on the investors who are not exploiting momentum’s insights in a similar way. Endnotes: 1.) In Table 1, we report long-only strategies in the “Recent Winners” and “Recent Losers” columns. These portfolios comprise stocks with the highest and lowest past returns, respectively. The “t-Stat” column reports the t-stat of the long-short portfolio returns. The long-short portfolio holds recent winners and shorts recent losers. Three versions of the momentum strategy are reported for the United States, because three different holding periods were used to measure recent returns. 2.) For example, Frazzini, Israel, and Moskowitz (2012) analyze trading costs associated with an actual implementation of a momentum strategy by an active manager. Their main finding is that, with thoughtful implementation, transaction costs in a momentum strategy can be significantly reduced. References: Arnott, Robert, and Stephen Vincent. 1986. “S&P Additions and Deletions: A Market Anomaly.” Journal of Portfolio Management, Vol. 13, No. 1 (Fall):29-33. Basu, Sanjoy. 1977. “Investment Performance of Common Stocks in Relation to Their Price-Earnings Ratios: A Test of the Efficient Market Hypothesis.” Journal of Finance, Vol. 32, No. 3 (June):663-682. Chordia, Tarun, and Lakshmanan Shivakumar. 2006. “Earnings and Price Momentum.” Journal of Financial Economics, Vol. 80, No. 3 (June):627-656. Frazzini, Andrea, Ronen Israel, and Tobias Moskowitz. 2012. ” Trading Costs of Asset Pricing Anomalies. ” Fama-Miller Working Paper, Chicago Booth Research Paper No. 14-05 (December 5). Goetzmann, William, and Mark Garry. 1986. “Does Delisting from the S&P 500 Affect Stock Price?” Financial Analysts Journal, Vol. 42, No. 2 (March/April):64-69. Harris, Lawrence, and Eitan Gurel. 1986. “Price and Volume Effects Associated with Changes in the S&P 500 List: New Evidence for the Existence of Price Pressures.” Journal of Finance, Vol. 41, No. 4 (September):815-829. Hsu, Jason, Vitali Kalesnik, Helge Kostka, and Noah Beck. Forthcoming. “Navigating the Factor Zoo.” Research Affiliates Working Paper. Jain, Prem. 1987. “The Effect on Stock Price from Inclusion In or Exclusion from the S&P 500.” Financial Analysts Journal, Vol. 43, No. 1 (January/February):58-65. Lamoureux, Christopher, and James Wansley. 1987. “Market Effects of Changes in the Standard & Poor’s 500 Index.” Financial Review, Vol. 22, No. 1 (February):53-69. Lynch, Anthony, and Richard Mendenhall. 1997. “New Evidence on Stock Price Effects Associated with Changes in the S&P 500 Index.” Journal of Business, Vol. 70, No. 3:351-383. Novy-Marx, Robert. 2015. ” Fundamentally, Momentum Is Fundamental Momentum .” NBER Working Paper No. 20984 (February). Novy-Marx, Robert, and Mihail Velikov. 2014. ” A Taxonomy of Anomalies and Their Trading Costs .” NBER Working Paper No. 20721 (December). Shleifer, Andrei. 1986. “Do Demand Curves for Stocks Slope Down?” Journal of Finance, Vol. 41, No. 3 (July):579-590. This article was originally published on researchaffiliates.com by Chris Brightman , Vitali Kalesnik , and Engin Kose . Disclaimer: The statements, views and opinions expressed herein are those of the author and not necessarily those of Research Affiliates, LLC. Any such statements, views or opinions are subject to change without notice. Nothing contained herein is an offer or sale of securities or derivatives and is not investment advice. Any specific reference or link to securities or derivatives on this website are not those of the author.